Enicepatide (CT388)
Metabolic Health · GLP-1/GIP dual agonist
Tier B-
Bottom line
Read Off Label grades Enicepatide (CT388) as B- (5.9/10) based on moderate evidence, high benefit magnitude, and a med-risk safety profile.
Roche/Genentech's lead injectable incretin (from the Carmot acquisition) — a dual GLP-1/GIP agonist in the tirzepatide mold.
Studied, labeled, or reported-use context: Subcutaneous injection, weekly (Phase 2 dosing) — Investigational; not individualized guidance.
What the evidence says
Roche/Genentech's lead injectable incretin (from the Carmot acquisition) — a dual GLP-1/GIP agonist in the tirzepatide mold. Phase 2 CT388-103 (48 wk) reported clinically meaningful weight loss, and Roche is advancing it to Phase 3 alongside petrelintide plus a Phase 2 multi-arm combination trial mid-2026; detailed figures were shared at ADA 2026 and a Roche investor event on 8 Jun 2026. A second Phase 2 (CT388-104) is running in obesity with type 2 diabetes. Industry-sponsored; peer-reviewed publication pending.
Mechanism
Dual GLP-1 and GIP receptor agonist (same class as tirzepatide) — pairs incretin appetite suppression with insulin sensitization for weight loss; injectable
Studied, labeled, or reported dose & route
Subcutaneous injection, weekly (Phase 2 dosing)
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about Enicepatide (CT388)'s effects?
- Read Off Label rates the evidence for Enicepatide (CT388) as Moderate and the benefit magnitude as high, producing an overall grade of B- (5.9/10). Roche/Genentech's lead injectable incretin (from the Carmot acquisition) — a dual GLP-1/GIP agonist in the tirzepatide mold.
- What safety findings are reported for Enicepatide (CT388)?
- Enicepatide (CT388) has a med risk profile in the database. Med (incretin-class GI: nausea, vomiting, diarrhea — dose-dependent) Legal status: Investigational (Phase 3 initiated 2026).
- What doses or routes are reported for Enicepatide (CT388)?
- Subcutaneous injection, weekly (Phase 2 dosing) This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does Enicepatide (CT388) work?
- Dual GLP-1 and GIP receptor agonist (same class as tirzepatide) — pairs incretin appetite suppression with insulin sensitization for weight loss; injectable
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.